2022 AUA Annual Meeting Highlights: Prostate Cancer
To better meet the educational needs of urologists and urologic healthcare providers, the AUA gathered from a variety of sources, including comprehensive literature searches and membership surveys to determine where gaps exist in the knowledge, proficiency, and practice in regards to prostate cancer.
The AUA Office of Education thanks the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support:
- Exact Sciences Corporation
- Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC
- Lantheus Medical Imaging
- Pfizer, Inc.
- Sanofi Genzyme
- Urologists in training
- Non-Physician providers involved in Urology
At the conclusion of the activity, participants will be able to:
- Explain the research and clinical publications from the past year on prostate cancer concerning risk stratification, screening, and biopsy methods.
- Highlight recent guideline updates in management of clinically localized prostate cancer.
- Describe the various disease states comprising advanced prostate cancer and advancement in management.
- Discuss new treatment available for patients with newly diagnosed M1 prostate and new treatment available for patients with M0 metastatic castrate-resistant prostate cancer.
- Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk, and utilize genetic testing results to improve outcomes for patients with metastatic prostate cancer.
- Describe which molecular tests can be performed on prostatectomy specimens and differentiate between somatic and germline mutations.
- Identify biomarkers used for initial diagnosis, risk stratification, posttreatment, and advanced disease.
COI Review Work Group Disclosures
COI Review Work Group Disclosures_2022.pdf
AUA Staff have nothing to disclose.
All relevant financial relationships have been mitigated.
Stephen Boorjian, MD
William Catalona, MD
Michael Cookson, MD,MHA
Douglas Dahl, MD
James Eastham, MD
Leonard Gomella, MD
Rachel Hastings, PA-C, MS
David Jarrard, MD
Lawrence Karsh, MD, FACS
Adam Kibel, MD
Stacy Loeb, MD
Todd Morgan, MD
Alicia Morgans, MD
Judd Moul, MD,FACS
Robert Nadler, MD
Kristen Scarpato, MD,FACS,MPH
Joseph Wagner, MD
METHOD OF PARTICIPATION:
To claim CME credit/hours of participation, the learner must read the content, complete the posttest, passing with 80% accuracy and submit the evaluation and credit request form.
Estimated time to complete this activity: 1.25 hours
Release Date: October 2022
Expiration Date: October 31, 2023
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:
- Peer review for valid, evidence-based content by the AUA COI Review Work Group.
- Attestation that clinical recommendations are evidence-based and free of commercial bias.
- Introduction of a debate format (point-counterpoint).
- Inclusion of moderated panel discussion with unbiased moderator.
- Publication of a parallel or rebuttal article for an article that is felt to be biased.
- Divestiture of the relationship by faculty.
- Recusal from controlling relevant aspects of planning.
- Selection of alternative faculty for specific topic.
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
- 1.25 AMA PRA Category 1 Credit™
- 1.25 Non-Physician Participation